Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 “All currently FDA-approved anti-VEGF therapies for retinal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback